Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GNYS about to say goodbye to sub .10!!!
.07 x .08 Lookin sweet!
sounds gooda to me..UTs 0599x08x1!!
Speculation on new Directors plans could drive this to .20+ with ease!!!
lookin gooda..imagine what a few big dog buyers could do from here.)bring um!))DF
Looks like a good start!!
GM all..lets roll!!!!!!!!!!!
U2 bro!! Sounds like we are going to be hearing much more about this new Director and what he is going to bring to the table for GNYS!!
lets hope so!)have a nice evenin bro and all!)see ya manana
The coming days/weeks will be great for GNYS, I am going long here, really like what I see, this is a rarity for these kind of stocks!!!
Only 3 MMs to .25 now.
nice..lookin to add more in the comin days myself..have a nice evenin bro and all..will see what manana brings!)DF
Saweet update Mr. Dream!!
DOMS just sold 5K and went to $1.01.
I just spoke with Keith Merrell briefly. He couldn't give out much info. but said that investors will be hearing from the company more often now that things are progressing including about the strategic aliance with Mr. Baker.
888-761-7771
I went to high school with his son
very nice background..huge for a OTCer especially imo..
lets hope he can make big things happen here..for pps too lol..and hopefully he brings some big time buyers along with him!)
Gordon D. Barker
Vice Chairman of the Board and Lead Independent Director
United Natural Foods, Inc.
Providence , RI
Sector: SERVICES / Food Wholesale
http://people.forbes.com/profile/gordon-d-barker/82648
64 Years Old
Gordon D. Barker has served as Vice Chair of the Board and Lead Independent Director since January 2010 and as a member of our Board of Directors since September 1999. Mr. Barker serves as our Chair of the Nominating and Governance Committee and as a member of our Audit Committee. Mr. Barker served on the Board of Directors of The Sports Authority, Inc. from April 1998 to May 2006. Mr. Barker served as a contract Chief Executive Officer for QVL Pharmacy Holdings, Inc., a privately-held entity, from October 2004 until February 2007. Mr. Barker served as Chief Executive Officer of Snyder's Drug Stores, Inc. from October 1999 to March 2004. Snyder's Drug Stores, Inc. filed for Chapter 11 bankruptcy in September 2003 and emerged from this filing in March 2004. Mr. Barker has served as President of Barker Holdings, LLC since January 2004. Mr. Barker has served as the principal of Barker Enterprises, an investment and consultant firm, since January 1997.
good idear imo
Gonna jump on as Mod here~
aha less than i thought..nice bro thanks..eom
Only 30k shares printed under .048 today.
agreed..a new chapter for GNYS being written imo!)bring it!
Almost record volume. More will notice this one soon.
lets see a strong EOD!)
er bring me more cheaps one the 2 lol
GNYS SS & SEC Filing History
Share Structure
Market Value1 $938,912 a/o Jan 10, 2011
Shares Outstanding 52,161,767 a/o Oct 15, 2010
SEC Filings
Form Type Received Period Ending Size Report
8-K Jan 11, 2011 Jan 3, 2011 13.6 KB [PDF] PDF [RTF] RTF [HTML] HTML
10-Q Oct 15, 2010 Aug 31, 2010 291.7 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
10-Q Jul 15, 2010 May 31, 2010 289.9 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
10-Q Apr 14, 2010 Feb 28, 2010 222.1 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
10-K Mar 1, 2010 Nov 30, 2009 519.6 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
10-Q Oct 15, 2009 Aug 31, 2009 206.0 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
SC 13D Aug 13, 2009 33.7 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
10-Q Jul 14, 2009 May 31, 2009 193.3 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
3 Jun 25, 2009 Jun 10, 2009 5.2 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
4 Jun 15, 2009 Jun 10, 2009
http://www.otcmarkets.com/stock/GNYS/company-info
Ask side thinning out. Time to move back up. That selling was stupid imo.
Yea, prolly some older holders who didnt see the news!!
Yes just saw the 8k, very nice, this is huge folks!!
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act
January 3, 2011
Date of Report
(Date of earliest event reported)
GeNOsys, INC.
(Exact name of registrant as specified in its charter)
Utah
000-49817
87-0671592
(State or Other Jurisdiction of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
86 N. University Ave., Suite 400
Provo, Utah 84601
(Address of Principal Executive Offices)
(801) 623-4751
(Registrant's Telephone Number)
N/A
(Former Name or Former Address if changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see general instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14-a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 3, 2011, the Board of Directors of GeNOsys, Inc. (the “Company”) appointed Gordon D. Barker and Keith L. Merrell as directors of the Company. Both will serve until the 2011 Annual Meeting of Shareholders and until their successor is duly elected and qualified. Mr. Merrell has served as our Chief Financial Officer and will continue in that position. Neither Mr. Barker or Mr. Merrell have been appointed to any committees of the Board of Directors.
There is no arrangement or understanding between either Mr. Barker or Mr. Merrell and any other person pursuant to which either was selected to serve as a director of the Company; neither has a family relationship with any director, executive officer or person nominated as such of the Company.
Since the beginning of the Company’s last fiscal year, there was no transaction or series of similar transactions, nor is there any currently proposed transaction or series of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $120,000 and in which Mr. Barker or Mr. Merrell, or members of their immediate family, had or will have a direct or indirect material interest.
On January 11, 2011, the Company issued a press release announcing the appointment of Mr. Barker and Mr. Merrell to the Company’s Board of Directors, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by this reference
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1
Press Release dated January 11, 2011
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
GeNOsys, INC.
Date: 1/11/2011
By/s/John W. R. Miller
President and director
GeNOsys Appoints Two Directors
PROVO, Utah.—January 11, 2011 GeNOsys, Inc. (OTCBB: GNYS) today announced the appointment of two additional directors. Mr. Gordon D. Barker and Mr. Keith L. Merrell have accepted board positions.
Mr. Barker served as the Chief Executive Officer of Thrifty Payless Drug Stores, Inc., a $5.1 billion company, and was instrumental in negotiating its merger with Rite-Aid Drugs. Mr. Barker currently serves on a number of Board of Directors for both public and private companies, including Vice Chairman and Lead Outside Independent Director of United Natural Foods, Inc., NuMedics, Inc., and American Consulting Technology & Research. Mr. Barker has also served as Chairman of the Juvenile Diabetes Research Foundation International.
Mr. Merrell has made valuable contributions as the Chief Financial Officer of GeNOsys. Prior to joining GeNOsys, he was the Chief Financial Officer of Specialized Health Products, Inc., a public company which developed and manufactured medical devices which required FDA approval before they could be introduced into the marketplace.
“We are very fortunate to have a person with the experience of Mr. Barker join our board. His vision and experience will be invaluable as we develop our product strategies,” stated Mr. John W.R. Miller, Chairman of the Board. “Mr. Merrell is also a valued addition to our board, bringing his financial, manufacturing and FDA regulatory experience.”
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company’s Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
--------------------------------------------------------------------------------
Contact:
GeNOsys, Inc.
Keith Merrell, 801-623-4751
kmerrell@genosysusa.com
Source: GeNOsys, Inc.
aha nice..now jus weed out this quick flippy and leave um in the dust kicking..sounds fitting to me lol
8K just out confirming the event...
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 3, 2011, the Board of Directors of GeNOsys, Inc. (the “Company”) appointed Gordon D. Barker and Keith L. Merrell as directors of the Company. Both will serve until the 2011 Annual Meeting of Shareholders and until their successor is duly elected and qualified. Mr. Merrell has served as our Chief Financial Officer and will continue in that position. Neither Mr. Barker or Mr. Merrell have been appointed to any committees of the Board of Directors.
There is no arrangement or understanding between either Mr. Barker or Mr. Merrell and any other person pursuant to which either was selected to serve as a director of the Company; neither has a family relationship with any director, executive officer or person nominated as such of the Company.
Since the beginning of the Company’s last fiscal year, there was no transaction or series of similar transactions, nor is there any currently proposed transaction or series of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $120,000 and in which Mr. Barker or Mr. Merrell, or members of their immediate family, had or will have a direct or indirect material interest.
On January 11, 2011, the Company issued a press release announcing the appointment of Mr. Barker and Mr. Merrell to the Company’s Board of Directors, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by this reference
yah caught my eye fer sure..
almost didnt even read pr after seeing pps up as much as it was when i got home lol..but chomped a few 06s jic it really wakes here today..will add accordinely wit ya in the comin days if get the opp
Nice one here
will try and get in next few days
MK
.06x.08 break out of single pennies its on imo!)
will see what haps with a dip im adding without im lettin it rideeeee..im not scared to hold for more than a few mins,hours,days like most other ihubbers nowadays it seems lol
very interesting..jus was digging into their website now..after digging through filings etc first..nice SS too imo!)
I don't see how we can go wrong on this one.
I LOVE when big dogs of his calibur join up with a lil ol OTCBBers like this ..could mean boookubucks for pps imo lol!)
lol spot on hahah
no laughing matter....tis the gas for this right?
yup im game to see what he can do to this!)eom
Scratching my head as to why more aren't buying this.
Gordon D. Barker didn't become a director here for nothing.
People will be chasing this one soon enough.
No joke!! Mr. Barker Bio is unreal!!
chased a few jus ta put a few away fer a bit..
i couldnt pass with that guys clout imo..
“It is imperative that GeNOsys brings its inexpensive portable new technology for generating Nitric Oxide gas to the bedside as quickly as possible to reduce the catastrophic effects tuberculosis has imposed on mankind.”
- Dr. Stephen D. Minton, M.D
“GeNOsys has completed the scientific process and has successfully developed commercially viable Nitric Gas Generator technology as well as the proprietary formulization for its consumable Tablet Medium. Now is the time to leverage that science and those assets to monetize our products, take them to the market and generate sustainable and reoccurring revenue.”
- Keith Merrell, CFO GeNOsys USA, Inc
http://www.genosysusa.com/home/what/
Presently nitric oxide is successfully being used with FDA approval in the treatment of newborns with respiratory illness. Ongoing medical research shows promise in the use of NO for the treatment of a myriad of diseases and illnesses partially due to its antiviral and bactericidal properties. GeNOsys’ nitric oxide generating systems will play an important role as laboratories develop further medical uses for this valuable gas and pursue additional FDA approvals.
http://www.genosysusa.com/
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
205
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
GeNOsys, Inc. Reports Recent Developments and Third Quarter 2008 Financial Results
PROVO, UT, Oct 16, 2008 (MARKET WIRE via COMTEX) -- GeNOsys, Inc. (OTCBB: GNYS), a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems, today announced recent key achievements and financial results for the third quarter and first nine months ended August 31, 2008.
Recent Business Development Milestones
-- Completed the research and development, engineering and construction
of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators. The
Company has been issued a patent on the GeNOx-B and has applied for a
patent on the GeNOx-P.
-- Completed preliminary research and development on the proprietary
tablet medium GeNOx-Tablet. Additionally, a formula for the bulk
manufacture of the tablet medium has been formulated. This formula will be
essential to carry out the business model of the Company as a commercially
viable reoccurring revenue producer of Nitric Oxide Gas Generators.
"The third quarter of fiscal 2008 was another active and productive period for GeNOsys, highlighted by the completion of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators," said Mr. Clark Mower, Chairman of the Board of Directors of GeNOsys. "Independent research has shown that Nitric Oxide gas, an FDA approved drug for use in the treatment of pulmonary hypertension in new-borns, may be an effective agent for the treatment of tuberculosis. Through our technology we are able to generate high purity Nitric Oxide for a significantly reduced cost. Now that we have completed this process, our plan includes a multi-track process of FDA and ISO 13485:2003 approvals in order to monetize our products.
Mr. Mower continued, "GeNOsys has a very large opportunity through the commercialization of our generators. Despite infecting nearly two billion people with the bacteria, which is one-third of the world's population, tuberculosis is "The Forgotten Plague," according to a recent article in Time magazine. The World Health Organization states that no new class of drug has been developed for its treatment in over thirty years. By 2010, the market for anti-tuberculosis drugs is projected to be between $612 and $670 million. The potential market for a new anti-tuberculosis drug is estimated to be between $316 and $345 million according to The Global Alliance for Tuberculosis Drug Development. Additionally, our research has shown that there are several other markets in which our generators have the potential to be used."
Financial results for the three months ended August 31, 2008
During the three-month period ended August 31, 2008, GeNOsys had a net loss of $332,349. This compares to a net loss of $239,738 for the comparable period ended August 31, 2007. Net loss per common share for each of the three month periods was $(.01).
Research and development ("R&D") expenses were $185,129 and $120,163, respectively, for the three-month periods ended August 31, 2008, and 2007, an increase of $64,966. The increase results from non-cash stock-based compensation charges, which were $15,488 higher in the 2008 period, from consulting and advisory board fees, and for additional work on both the nitric oxide generator and the tablet formulation to bring them to finalization. As the work on document preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $147,152 and $122,907, respectively, for the three-month periods ended August 31, 2008 and 2007, an increase of $24,245. The increase results from the non-cash stock-based compensation charge, which was $22,287 higher in 2008 than in the comparable 2007 period. Excluding that charge, general and administrative expenses would have remained flat in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses were incurred in raising the additional capital needed to fund our operations and bring our products to market.
Financial results for the nine months ended August 31, 2008
During the nine-month period ended August 31, 2008, GeNOsys had a net loss of $970,224. This compares to a net loss of $657,293 for the comparable period ended August 31, 2007. Net loss per common share for these periods was $(.02) and $(.01), respectively.
Research and development ("R&D") expenses were $515,832 and $319,086, respectively, for the nine-month periods ended August 31, 2008 and 2007. A significant portion of the $196,746 increase in research and development expenditures resulted from higher non-cash stock-based compensation charges in 2008, which exceeded the 2007 charge by $92,326. Increases were also seen in consulting fees and advisory board fees for additional work on both the nitric oxide generator and the tablet formulation. As the documentation preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $456,656 and $355,396, respectively, for the nine-month periods ended August 31, 2008 and 2007. The increase results from non-cash stock-based compensation charges, which were $132,859 higher in 2008 than 2007. Excluding that charge, general and administrative expenses would have decreased by $31,599 in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses are incurred in raising the additional capital needed to fund operations and bring the products to market.
About GeNOsys, Inc.
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas is one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company's Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
From
Beginning
of
Development
Stage
(June 30,
2005)
For the Three Months For the Nine Months To August
Ended August 31, Ended August 31, 31,
2008 2007 2008 2007 2008
----------- ----------- ----------- ----------- -----------
Revenues $ - $ - $ - $ - $ -
Cost of sales - - - - -
----------- ----------- ----------- ----------- -----------
Gross margin - - - - -
Operating
expenses:
Research and
development 185,129 120,163 515,832 319,086 1,735,288
General and
administra-
tive 147,152 122,907 456,656 355,396 1,733,279
----------- ----------- ----------- ----------- -----------
Total
operating
expenses 332,281 243,070 972,488 674,482 3,468,567
----------- ----------- ----------- ----------- -----------
Net income
(loss) from
operations (332,281) (243,070) (972,488) (674,482) (3,468,567)
----------- ----------- ----------- ----------- -----------
Other income
(expense):
Interest
income 47 3,332 2,379 17,503 82,198
Gain (loss)
on disposal
of asset - - - (414) (414)
Other income
(expense) - - - 100 100
----------- ----------- ----------- ----------- -----------
Total other
income
(expense),
net 47 3,332 2,379 17,189 81,884
----------- ----------- ----------- ----------- -----------
Net income
(loss) before
income Taxes (332,234) (239,738) (970,109) (657,293) (3,386,683)
----------- ----------- ----------- ----------- -----------
Provision
(benefit) for
income Tax 115 - 115 - 415
----------- ----------- ----------- ----------- -----------
Income (loss)
from continuing
operations (332,349) (239,738) (970,224) (657,293) (3,387,098)
Discontinued
operations:
Loss from
discontinued
operations,
net of tax - - - - (2,131)
Gain on
disposal of
discontinued
operations,
net of tax - - - - 71,253
----------- ----------- ----------- ----------- -----------
Net income
(loss) $ (332,349)$ (239,738) $ (970,224)$ (657,293)$(3,317,976)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
continuing
operations $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
discontinued
operations $ - $ - $ - $ - $ -
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted
weighted
average
number of
common shares
outstanding 46,148,787 45,668,031 46,002,850 45,668,031 45,252,720
=========== =========== =========== =========== ===========
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
From
Beginning
of
Development
For the Nine For the Nine Stage (June
Months Ended Months Ended 30, 2005)
August August to August
31, 2008 31, 2007 31, 2008
------------ ------------ ------------
Cash flows from operating
activities:
Net loss $ (970,224) $ (657,293) $ (3,317,976)
Adjustments to reconcile net
loss to net cash used in
operating activities:
Depreciation and amortization 38,954 34,200 97,135
Gain on the disposal of
discontinued Operations - - (71,253)
Loss on disposal of equipment - 414 414
Stock-based compensation 281,616 56,431 420,355
Decrease in cash from
discontinued operations - - (6,020)
Stock issued for services 8,536 - 278,536
Changes in operating assets
and liabilities:
(Increase) Decrease in
prepaid expenses (37,197) 64,956 (40,943)
Increase (Decrease) in
accounts payable 55,048 14,030 68,197
Increase (Decrease) in
related party liabilities (9,340) - 4,000
Increase (Decrease) in
accrued liabilities 195,522 (38,358) 209,729
Increase (Decrease) in tax
payable - - 200
------------ ------------ ------------
Net cash used in
operating activities (437,085) (525,620) (2,357,626)
------------ ------------ ------------
Cash flows from investing
activities:
Purchase of intangible assets (27,543) (33,634) (69,672)
Purchase of equipment (1,021) (18,200) (207,501)
------------ ------------ ------------
Net cash provided by
(used in) investing
Activities (28,564) (51,834) (277,173)
------------ ------------ ------------
Cash flows from financing
activities:
Issuance of common stock for
cash 153,500 - 2,574,604
Proceeds from related party
loans 36,000 - 36,000
Cash from discontinued
operations - - (19,777)
------------ ------------ ------------
Net cash provided by
financing activities 189,500 - 2,590,827
------------ ------------ ------------
Net increase (decrease) in cash (276,149) (577,454) (43,972)
Cash at beginning of the period 280,105 904,715 47,928
------------ ------------ ------------
Cash at end of the period $ 3,956 $ 327,261 $ 3,956
============ ============ ============
Supplemental Disclosure
Information
Cash paid during the year for:
Interest $ - $ - $ 750
Income/franchise taxes - - 200
Stock issued for services 8,536 - 278,536
============ ============ ============
Contact:
Alliance Advisors, LLC
Alan Sheinwald
President
(914) 669-0222
Email Contact
Mark McPartland
Vice President
(910) 686-0455
Email Contact
GeNOsys, Inc.
Michael Dancy
(801) 746-3570
Email Contact
SOURCE: GeNOsys, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |